Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Farletuzumab + Paclitaxel in Platinum-Resistant Ovarian Cancer
NCT00738699Phase 2Terminated
- Sponsor
- Morphotek
- Start
- Sep 2008
- Primary completion
- Dec 2011
- Modality
- Monoclonal Antibodies
- Countries
- 6
01
Overview
A Phase 2 trial of farletuzumab in ovarian cancer, sponsored by Morphotek. Started Sep 2008; status: terminated.
02
Drugs
farletuzumab
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT00738699.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00738699.